At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 130 enrolled
Drug / intervention
High Dose SJP-0035 Ophthalmic Solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of Two Dose Concentrations of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders
In Brief
A Phase 2 clinical trial evaluating High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, and 1 other intervention for Corneal Epithelial Disorders. Completed, enrolled 130 participants across 19 sites.
Detailed Summary
The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorneal Epithelial Disorders
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartSep 2016
First PostedOct 2016
Primary CompletionMay 2017
TodayJul 2026
First PostedOct 11, 2016
Enrollment StartSep 1, 2016
Primary CompletionMay 3, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.7 years ago
Interventions
High Dose SJP-0035 Ophthalmic Solutiondrug
0.001% SJP-0035 Ophthalmic Solution
Low Dose SJP-0035 Ophthalmic Solutiondrug
0.0002% SJP-0035 Ophthalmic Solution
Vehicle of SJP-0035 Ophthalmic solutiondrug
0% SJP-0035 Ophthalmic Solution